NDAORALSUSPENSION
Approved
Jul 2019
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
20
Data completeness
6/8 — Strong
KATERZIA (amlodipine) by R-Pharm US is (calcium ion antagonist or slow-channel blocker) that inhibits the transmembrane influx of calcium ions into vascular smooth muscle and cardiac muscle. First approved in 2019.
Drug data last refreshed 3h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
KATERZIA (amlodipine) is an oral calcium channel antagonist approved in 2019 as a suspension formulation for hypertension and angina. It works by inhibiting calcium ion influx into vascular smooth muscle and cardiac muscle, causing peripheral vasodilation and reducing blood pressure and myocardial oxygen demand. The drug selectively affects vascular smooth muscle more than cardiac muscle, with a gradual onset of action due to its ionized nature at physiologic pH.
$0.001BPart D
Peak12.8 years to LOEThis product is in peak lifecycle with minimal Part D spending ($1M, 1,800 claims in 2023), suggesting a niche commercial footprint and likely small, focused brand team.
Mechanism of Action
(calcium ion antagonist or slow-channel blocker) that inhibits the transmembrane influx of calcium ions into vascular smooth muscle and cardiac muscle. Experimental data suggest that amlodipine binds to both dihydropyridine and nondihydropyridine binding sites. The contractile processes of cardiac…
Indications
Worked on KATERZIA at R-Pharm US? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.